76,242 Shares in Edwards Lifesciences Co. (NYSE:EW) Bought by Caisse Des Depots ET Consignations

Caisse Des Depots ET Consignations purchased a new stake in Edwards Lifesciences Co. (NYSE:EW) during the fourth quarter, HoldingsChannel.com reports. The fund purchased 76,242 shares of the medical research company’s stock, valued at approximately $5,644,000.

Several other hedge funds have also bought and sold shares of the stock. Advisors Asset Management Inc. lifted its position in shares of Edwards Lifesciences by 7.7% in the third quarter. Advisors Asset Management Inc. now owns 11,856 shares of the medical research company’s stock worth $782,000 after buying an additional 852 shares in the last quarter. Larson Financial Group LLC grew its holdings in shares of Edwards Lifesciences by 199.1% in the third quarter. Larson Financial Group LLC now owns 4,391 shares of the medical research company’s stock valued at $290,000 after purchasing an additional 2,923 shares in the last quarter. Daiwa Securities Group Inc. increased its position in Edwards Lifesciences by 1.5% in the third quarter. Daiwa Securities Group Inc. now owns 90,122 shares of the medical research company’s stock worth $5,947,000 after purchasing an additional 1,374 shares during the last quarter. Dynamic Technology Lab Private Ltd purchased a new stake in Edwards Lifesciences during the third quarter valued at $825,000. Finally, Truvestments Capital LLC purchased a new stake in Edwards Lifesciences during the third quarter valued at $109,000. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Insider Activity at Edwards Lifesciences

In other news, VP Donald E. Bobo, Jr. sold 9,500 shares of the firm’s stock in a transaction dated Thursday, March 13th. The stock was sold at an average price of $67.96, for a total value of $645,620.00. Following the completion of the transaction, the vice president now directly owns 46,936 shares in the company, valued at $3,189,770.56. This trade represents a 16.83 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, VP Daniel J. Lippis sold 500 shares of the company’s stock in a transaction that occurred on Thursday, January 16th. The shares were sold at an average price of $68.76, for a total value of $34,380.00. Following the completion of the sale, the vice president now owns 23,189 shares in the company, valued at approximately $1,594,475.64. This represents a 2.11 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 62,553 shares of company stock valued at $4,513,064 in the last ninety days. Corporate insiders own 1.29% of the company’s stock.

Edwards Lifesciences Stock Down 0.2 %

Edwards Lifesciences stock opened at $71.12 on Thursday. The firm has a market cap of $41.81 billion, a P/E ratio of 10.20, a P/E/G ratio of 4.82 and a beta of 1.12. The company has a quick ratio of 2.89, a current ratio of 3.46 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Co. has a twelve month low of $58.93 and a twelve month high of $96.12. The business has a fifty day moving average of $71.45 and a two-hundred day moving average of $70.45.

Edwards Lifesciences (NYSE:EW) last posted its earnings results on Tuesday, February 11th. The medical research company reported $0.59 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.55 by $0.04. Edwards Lifesciences had a return on equity of 19.40% and a net margin of 72.93%. On average, analysts forecast that Edwards Lifesciences Co. will post 2.45 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on EW shares. Truist Financial restated a “hold” rating and issued a $78.00 target price (up from $70.00) on shares of Edwards Lifesciences in a report on Thursday, December 5th. Morgan Stanley boosted their price objective on Edwards Lifesciences from $70.00 to $75.00 and gave the stock an “equal weight” rating in a research note on Wednesday, February 12th. Stifel Nicolaus raised Edwards Lifesciences from a “hold” rating to a “buy” rating and raised their price objective for the company from $75.00 to $90.00 in a research note on Thursday, January 30th. Bank of America raised Edwards Lifesciences from a “neutral” rating to a “buy” rating and boosted their target price for the company from $82.00 to $90.00 in a research report on Monday, December 16th. Finally, Citigroup raised their price target on Edwards Lifesciences from $81.00 to $83.00 and gave the stock a “buy” rating in a research report on Wednesday, December 11th. One equities research analyst has rated the stock with a sell rating, fourteen have given a hold rating and eleven have given a buy rating to the company. Based on data from MarketBeat, Edwards Lifesciences has an average rating of “Hold” and a consensus price target of $79.95.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.